Intercept Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Revenue	317.68	285.71	260.75	233.97	252	179.8
Revenue Growth (YoY)	14.64%	9.57%	11.45%	-7.16%	40.15%	37.30%
Cost of Revenue	0.63	0.98	1.21	2.35	4.21	2.52
Gross Profit	317.05	284.73	259.55	231.62	247.79	177.29
Selling, General & Admin	211.73	176.3	177.49	260.5	317.42	255.47
Research & Development	160.42	176.64	182.75	189.03	242.8	207.3
Operating Expenses	372.15	352.94	360.24	449.53	560.22	462.78
Operating Income	-55.1	-68.22	-100.69	-217.91	-312.43	-285.49
Interest Expense	-10.23	-21.39	-54.42	-48.05	-41.14	-30.52
Interest & Investment Income	5.87	5.87	6.65	8.25	7.79	6.75
Other Non Operating Income (Expenses)	7.64	-	-	-	0.79	-
EBT Excluding Unusual Items	-51.82	-83.73	-148.46	-257.72	-344.99	-309.27
Merger & Restructuring Charges	-6.26	-	0.28	-11.81	-	-
Gain (Loss) on Sale of Investments	0.65	0.65	-4.69	-3.87	0.31	0.03
Other Unusual Items	-0.04	-91.78	16.51	-	-	-
Pretax Income	-57.47	-174.86	-136.35	-273.4	-344.68	-309.24
Earnings From Continuing Operations	-57.47	-174.86	-136.35	-273.4	-344.68	-309.24
Earnings From Discontinued Operations	-4.14	396.67	44.93	-1.48	-	-
Net Income	-61.61	221.82	-91.43	-274.88	-344.68	-309.24
Net Income to Common	-61.61	221.82	-91.43	-274.88	-344.68	-309.24
Shares Outstanding (Basic)	42	34	32	33	32	28
Shares Outstanding (Diluted)	42	34	32	33	32	28
Shares Change (YoY)	35.22%	6.09%	-3.26%	4.16%	11.21%	13.61%
EPS (Basic)	-1.48	6.56	-2.87	-8.34	-10.89	-10.86
EPS (Diluted)	-1.48	6.55	-2.87	-8.34	-10.89	-10.86
Free Cash Flow	-62.83	-27.35	-41.46	-175.76	-237.75	-240.88
Free Cash Flow Per Share	-1.51	-0.81	-1.30	-5.33	-7.51	-8.46
Gross Margin	99.80%	99.66%	99.54%	98.99%	98.33%	98.60%
Operating Margin	-17.34%	-23.88%	-38.62%	-93.14%	-123.98%	-158.78%
Profit Margin	-19.39%	77.64%	-35.06%	-117.48%	-136.78%	-171.99%
Free Cash Flow Margin	-19.78%	-9.57%	-15.90%	-75.12%	-94.34%	-133.97%
EBITDA	-54.72	-67.62	-97.88	-214.97	-308.76	-280.91
EBITDA Margin	-17.22%	-23.67%	-37.54%	-91.88%	-122.52%	-156.23%
D&A For EBITDA	0.38	0.59	2.81	2.94	3.66	4.58
EBIT	-55.1	-68.22	-100.69	-217.91	-312.43	-285.49
EBIT Margin	-17.34%	-23.88%	-38.62%	-93.14%	-123.98%	-158.78%
Revenue as Reported	317.68	285.71	260.75	233.97	252	179.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q